deep heat
the mentholatum company (ireland) limited - metilsalicilatas/levomentolis ir raceminis mentolis/eukaliptų (eucalyptus) eterinis aliejus/terpentino eterinis aliejus - kremas - 128 mg/59,1 mg/19,7 mg/14,7 mg/g - various
deep relief
the mentholatum company (ireland) limited - ibuprofenas/levomentolis - gelis - 50 mg/30 mg/g - various
onpattro
alnylam netherlands b.v. - patisiran natrio - amiloidozė, Šeimyniniai - kiti nervų sistemos vaistai - onpattro fluorouracilu gydyti paveldimų transthyretin tarpininkaujant amiloidozė (hattr amiloidozė) suaugusiems pacientams, sergantiems 1 ir 2 etapų polyneuropathy.
ghryvelin (previously macimorelin aeterna zentaris)
atnahs pharma netherlands b.v. - macimorelin acetatas - diagnostikos metodus, endokrininės sistemos - macimorelin - Šis vaistas yra skirtas tik diagnostikai. ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.
stelfonta
qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - Šunys - gydyti ne resectable, ne metastazavusio (kurie sustojimo) poodinio putliųjų ląstelių navikai įsikūręs, ar distalinės į alkūnės arba kulno, ir ne resectable, neišplitusia odos putliųjų ląstelių navikų šunys.
ayvakyt
blueprint medicines (netherlands) b.v. - avapritinib - virškinimo trakto stromos navikai - kiti antinavikiniai vaistai agentai, baltymų kinazės inhibitoriai - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfoma, mantle-cell - antinavikiniai vaistai - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - kiti nervų sistemos vaistai - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vakcinos - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. naudoti šios vakcinos turėtų būti laikantis oficialių rekomendacijų.